New study tests safer pain relief for oral cancer patients
NCT ID NCT07606638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two pain management strategies for adults with oral cancer who have moderate to severe pain. One group receives the opioid tramadol, while the other gets a combination of pregabalin and naproxen sodium. Over 7 days, researchers measure pain reduction, side effects, and patient satisfaction to see which approach works better and is safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tramadol (opioid) and pregabalin plus naproxen sodium
- What this could lead to
- If this trial succeeds, it could show that a non-opioid combination (pregabalin + naproxen) works as well as or better than tramadol for oral cancer pain, offering a safer alternative with fewer side effects.
- What could go wrong
- This is a small, single-center study with only 98 participants, so results may not apply to everyone. The short 7-day treatment period doesn't show long-term effects or risks like dependence or tolerance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Hospital, Lahore
Lahore, Punjab Province, 54000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple test spot oral cancer and gum disease early?
- Can a glowing drug light up head and neck tumors?
- Less may be more: testing a gentler neck dissection for oral cancer
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- New tracheostomy tube holder aims to cut infections and boost comfort
- HIV and cancer: study seeks to uncover hidden risk factors